NYSEARCA:NNVC - NYSE Arca - US6300873022 - Common Stock - Currency: USD
1.42
+0.07 (+5.19%)
The current stock price of NNVC is 1.42 USD. In the past month the price increased by 17.36%. In the past year, price increased by 29.09%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
NanoViricides, Inc. is a clinical stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484 US
CEO: Anil Diwan
Employees: 7
Company Website: https://www.nanoviricides.com/
Investor Relations: http://www.nanoviricides.com/investorinfo.html
Phone: 12039376137
The current stock price of NNVC is 1.42 USD. The price increased by 5.19% in the last trading session.
The exchange symbol of NANOVIRICIDES INC is NNVC and it is listed on the NYSE Arca exchange.
NNVC stock is listed on the NYSE Arca exchange.
7 analysts have analysed NNVC and the average price target is 6.63 USD. This implies a price increase of 366.9% is expected in the next year compared to the current price of 1.42. Check the NANOVIRICIDES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NANOVIRICIDES INC (NNVC) has a market capitalization of 22.21M USD. This makes NNVC a Nano Cap stock.
NANOVIRICIDES INC (NNVC) currently has 7 employees.
NANOVIRICIDES INC (NNVC) has a support level at 1.31 and a resistance level at 1.5. Check the full technical report for a detailed analysis of NNVC support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NNVC does not pay a dividend.
NANOVIRICIDES INC (NNVC) will report earnings on 2025-05-12.
NANOVIRICIDES INC (NNVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
The outstanding short interest for NANOVIRICIDES INC (NNVC) is 0.97% of its float. Check the ownership tab for more information on the NNVC short interest.
ChartMill assigns a technical rating of 8 / 10 to NNVC. When comparing the yearly performance of all stocks, NNVC is one of the better performing stocks in the market, outperforming 93.72% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to NNVC. NNVC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months NNVC reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 11.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -80.94% | ||
ROE | -90.16% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to NNVC. The Buy consensus is the average rating of analysts ratings from 7 analysts.